Kiniksa Pharmaceuticals International (KNSA) Finished Goods (2021 - 2023)

Kiniksa Pharmaceuticals International's Finished Goods history runs 3 years deep, the most recent figure standing at $12.9 million for Q4 2023.

• Quarterly Finished Goods fell 15.85% year-over-year to $12.9 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $12.9 million (down 15.85% YoY) and the FY2023 annual result came in at $12.9 million, down 15.85% from the prior year.
• Finished Goods was $12.9 million for Q4 2023 at Kiniksa Pharmaceuticals International, up from $12.2 million in the prior quarter.
• Across five years, Finished Goods topped out at $19.9 million in Q2 2022 and bottomed at $1.4 million in Q3 2021.
• A 3-year average of $10.4 million and a median of $12.5 million in 2023 frame the typical range for Finished Goods.
• Annual changes were most pronounced in 2022 — Finished Goods jumped 927.48% — and 2023, when it retreated 24.22%.
• Kiniksa Pharmaceuticals International's Finished Goods stood at $3.7 million in 2021, then jumped by 315.97% to $15.3 million in 2022, then slipped by 15.85% to $12.9 million in 2023.
• Business Quant data shows KNSA's Finished Goods at $12.9 million in Q4 2023, $12.2 million in Q3 2023, and $17.3 million in Q2 2023.